EMAIL DETAILS

Hi Eric,

I forwarded the attached to Arlene. We have our annual shareholder meeting
next week, hence Evan has a lot housekeeping paperwork to do in front of
that meeting. However, we will be getting a draft agreement over to you
shortly. We do not require NDA¹s due to our IP position.

Thank you for your efforts to date.

Derrick W. Johns
CEO and Founder
www.difusiontech.com

"All Truths are easy to understand once discovered,
the point is to discover them² - Galileo

(512) 863-7777 o
(512) 284-3338 c


From: Derrick Johns <derrick@difusiontech.com>
Date: Wednesday, November 19, 2014 at 8:37 AM
To: <abusch@rosemontseneca.com>
Subject: DiFusion Intro


Arlene,

Paul Rowan asked me to forward the attached folder for review. I have
included several published papers, patents and powerpoint presentations.
It is important to note that this technology has many applications up and
and above an antimicrobial surgical polymer. There is ample research which
suggest having the ability to control metallic cations in medical scaffolds
can also promote osteogenesis (bone growth) and possibly even target cancer
cells. (See below).

Thank you for referring this over, I look forward to meeting you soon.

Please see the surgeon videos on our home page for detail on the massive
reimbursement advantages this technology affords.

Derrick W. Johns
CEO and Founder
www.difusiontech.com

"All Truths are easy to understand once discovered,
the point is to discover them² - Galileo

(512) 863-7777 o
(512) 284-3338 c